Nestin and FLT1 in Renal Cell Carcinoma
Author Information
Author(s): Elkady Noha, Abdelaziz Reham Ahmed, Abdelmoneum Rasha Adel, Ghonaimy Ahmed S, Allam Dina Mohamed
Primary Institution: Menoufia University, Egypt
Hypothesis
This study aimed to evaluate the expression of Nestin and FLT1 in RCC and their prognostic impact.
Conclusion
Nestin and FLT1 expressions in RCC may be associated with aggressive tumor features and short patients’ overall survival.
Supporting Evidence
- Nestin was expressed in 65% of cases and FLT1 in 73.3% of cases.
- Both markers were significantly associated with aggressive tumor parameters.
- High MVD measured by Nestin was associated with short overall survival.
Takeaway
This study found that two proteins, Nestin and FLT1, can help doctors understand how aggressive a kidney cancer might be and how long patients might live.
Methodology
This retrospective study included sixty cases of RCC, with immunohistochemical staining of Nestin and FLT1, and evaluation of microvessel density (MVD).
Limitations
The absence of funding and the relatively small sample size limited the investigation.
Participant Demographics
{"mean_age":57.4,"gender_distribution":{"male":38,"female":22},"tumor_types":{"clear_cell":36,"papillary":8,"other":16}}
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website